• January 7, 2020

    In 2019 Tchaikapharma (BSE:7TH) affirmed its leadership through successful development of scientific projects based on the advanced research on the development and integration of innovative combo medicines, some of which never used before in the global medical practice. Series of laboratory research and clinical studies are conducted in collaboration with European and American companies, namely in the fields of cardiology, endocrinology and neurology.


    Combination of different well-known molecules in PolyPill has a beneficial effect on patients, whose increased value is represented by cost-effectiveness and improved therapeutic outcomes and life comfort. Combination of substances provides the attractive opportunity to optimize admission of various medicaments in one dosage. Tchaikapharma is implementing a strategy of prioritizing patient care above all. Evidently holds on to the principles of corporative responsibility towards the community and constant innovative growth, thus managing to enter foreign markets with main focus on European countries.


    In an environment of increased pressure pension funds and minimal or negative interest rates of deposits in the majority of European countries, long-term investments in Tchaikapharma (BSE:7TH) proved themselves fruitful for numerous investors. Essentially, this trend is projected to continue through strengthening market presence outside Bulgaria.


    Tchaikapharma started crucial consolidation of its resources in order to expand its business model beyond our borders. So far, 10 pharmaceutical products have been registered in 7 EU countries. The initial stage of market entry seems to be highly optimistic.


    Taking into account the great market opportunities and bright prospects of Tchaikapharma’s modern portfolio, in 2019 started the design and construction of a third state-of-the-art manufacturing complex for tablets, capsules and sterile ampules, which will be dedicated to supply European markets. The new facility will feature robotized equipment and a next-gen AI process control panel, including a modern storage for pharmaceutical forms that are ready to set.


    Deeper entry in the fields of oncological drugs R&D is supported by another revolutionary project in 2020 – a projected investment in NGS (next generation sequencing) laboratory that will enable elaborate research of human gene and detection of mutation which are highly relatable to specific oncological diseases. This would allow therapy to be optimized personally for each patient, providing maximum suitability and efficacy.


    Therefore, the possibility of positive therapeutic response is increased many-fold, and side effects inherent to conventional methods of oncological therapy, limited. Consequently, such personalized therapeutic approach based on NGS analysis, minimizes the risk of disease relapse. The high-tech laboratory will be one of its kind in the Balkans and will provide patients form the region (East of Munich) health technologies solely available in some countries in Western Europe and the USA.


    Today, Tchaikapharma is one of the largest companies on the Bulgarian Stock Exchange, with market cap of 895 million BGN as of the end of 2019 – trustworthy of its numerous investors and immense prospects.


    The original article is available here in Bulgarian.

  • December 5, 2019

    The newest addition to Tchaikapharma High Quality Medicines Inc. prescription drugs (Rx) product list are the following:


    – Zornichka (chlorthalidone) – for the treatment of arterial hypertension, essential or renovascular, or isolated systolic hypertension;


    – PlaquEx Combi (clopidogrel/acetylsalicylic acid) – for the secondary prevention of acute cardiovascular events;


    – Methylprednisolone -Tchaikapharma (methylprednisolone) – for the treatment of endocrine, rheumatic, collagenosis and immune-complex, skin, eye, gastrointestinal, respiratory,  hematological, oncology and edema diseases, as well as allergic conditions.

  • November 14, 2019

    Numerous spectators attended the traditional restoration of the Battle of Slivnitsa. Many volunteers were involved in the recreation of the events of the Serbo-Bulgarian War of 1885.




    This year again, Tchaikapharma’s team took part in commemoration, as they traditionally participate in the recreation of historical events.


    Оn November 7, 2005, the company built and offered to the citizens a monument in memory of the killed Bulgarian officers, NCOs and soldiers on the occasion of the 120th anniversary of the victory in Slivnitsa of the Bulgarian army in the Serbian-Bulgarian war. The monument was inaugurated in the presence of the Vice President of the Republic of Bulgaria, Gen. Angel Marin, war veterans, representatives of military organizations and numerous citizens.




    The recreation organizer is the national “Tradition” society – a voluntary, nongovernmental patriotic organization aimed at promoting and preserving patriotic traditions of military symbols and rituals, national values, weapons as a tribal memory, organizing and participating in recreating and events and battles of Bulgarian history.




    After the historical recreation, the participants took a picture in front of the monument built by Tchaikapharma.

  • October 23, 2019

    Bulgaria’s Young Talents in The Field of Synthetic Biology Expressed Their Gratitude for The Support Provided


    Tchaikapharma High Quality Medicines Ltd. supports Bulgaria’s Team of Synthetic Biology young specialists at their participation in the biggest bio engineering contest on the Planet – iGEM. The competition takes place in Boston, USA each year and accommodates more than 350 university teams from around the world. The Bulgarian team consists of future scientists and doctors from the Sofia University “Saint Kliment Ohridski”.

    Besides being a platform for young scientist development, iGEM is also looking to obtain solutions to socially viable challenges. The Bulgarian project is dedicated to a global issue – resistance of pathogenic microbes to antibiotics. Antimicrobial resistance is one of the main threats to human and animal health. It causes more than 33 000 deaths in the European Union each year and financial losses are over 1.5 billion Euro.

    The negative tendency for constant growth of the number of infections such as tuberculosis, pneumonia and others, which are caused by pathogenic microbes that are resistant to the currently applied medicines, define the antimicrobial resistance as a global issue with a significant relevance. According to the World Health Association and the European Commission, if no new treatments are found up to 2050, 10 million people will die every year due to infections, caused by multi-resistant bacteria.

    The team will travel at the end of the month and is currently preparing for the competition at the Sofia Tech Park labs.

  • Tchaikapharma High Quality Medicines ranks among the leaders in the Prescription Drugs (Rx) market for the past 12 months (as of June 2019).


    The ranking “Top 10 Corporations in the market for prescription products” of the world’s leading analytics company IQVIA  takes into account sales at end-customer prices, with Tchaikapharma increasing its market share is now ranked second by number of packages sold.


    The top ten Rx companies in Bulgaria hold 45% of the total market for prescription drugs.